Press release
Rheumatoid Arthritis Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
Unlock key insights into the Rheumatoid Arthritis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Rheumatoid Arthritis Therapeutics Market Outlook [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Rheumatoid Arthritis Market Report
* In April 2025, Immunovant Sciences GmbH announced a study consists of several periods. During the Screening Period (5 weeks) participants will undergo screening procedures to determine eligibility. In Period 1 (Open-Label Treatment), all eligible participants will receive open-label treatment with IMVT-1402 at a dose of 600 mg subcutaneous (SC) once weekly (QW) for 16 weeks.
* In April 2025, Eli Lilly and Company organized a study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).
* In April 2025, Sanofi conducted Phase 2 study, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive.
* Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period.
* Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023.
* In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023.
* The leading Rheumatoid Arthritis Companies such as R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others.
* Promising Rheumatoid Arthritis Pipeline Therapies such as BMS-582949, etanercept, Filgotinib Maleate, Hemay007 800 mg, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
Stay ahead in the competitive landscape of the Rheumatoid Arthritis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Rheumatoid Arthritis Treatment Market Size [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Rheumatoid Arthritis Epidemiology Segmentation in the 7MM
* Total Rheumatoid Arthritis Prevalent cases
* Rheumatoid Arthritis Diagnosed Prevalent cases
* Rheumatoid Arthritis Gender-specific Prevalent cases
* Rheumatoid Arthritis Age-specific Prevalent cases
* Rheumatoid Arthritis Severity-specific Prevalent cases
* Rheumatoid Arthritis Patients on targeted therapies
* Rheumatoid Arthritis Line-Wise Treated Cases
Download the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Prevalence [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Rheumatoid Arthritis Marketed Drugs
* OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis.
* RINVOQ (upadacitinib): AbbVie
RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.
Rheumatoid Arthritis Emerging Drugs
* Rabeximod (Rob 803): Cyxone
Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNF monoclonal antibodies and oral JAK inhibitors.
* Imvotamab: IGM Biosciences
Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells.
To learn more about Rheumatoid Arthritis Treatment guidelines, visit @ Rheumatoid Arthritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Rheumatoid Arthritis Companies
R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others
Rheumatoid Arthritis Market Outlook
Treatment of patients with RA aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA.
Explore the dynamics of the Rheumatoid Arthritis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Rheumatoid Arthritis Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Rheumatoid Arthritis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Rheumatoid Arthritis Companies- R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Pfizer, Akros Pharma/Japan Tobacco, Pfizer/Philogen, AbbVie, Pfizer, and SynAct Pharma and others.
* Rheumatoid Arthritis Pipeline Therapies- BMS-582949, etanercept, Filgotinib Maleate, Hemay007 800 mg, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
* Rheumatoid Arthritis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Rheumatoid Arthritis Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement
Table of Contents
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Flow Methodology
6 Rheumatoid Arthritis Market Overview at a Glance
7 Disease Background and Overview
8 Treatment and Management of Rheumatoid Arthritis
9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology)
10 Treatment Guidelines for RA (National Institute for Health and Care Excellence)
11 Guidelines for Management of RA (American College of Rheumatology)
12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology)
13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR))
14 Treatment Algorithm
15 Epidemiology and Patient Population of 7MM
16 Patient Journey
17 Key Endpoints in Rheumatoid Arthritis Clinical Trials
18 Marketed Drugs
19 Emerging Drugs
20 Rheumatoid arthritis: 7MM Market Analysis
21 Unmet Needs
22 SWOT Analysis
23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies
24 KOL Views
25 Appendix
26 DelveInsight Capabilities
27 Disclaimer
28 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rheumatoid-arthritis-treatment-market-size-in-7mm-is-expected-to-grow-at-a-decent-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatoid Arthritis Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight here
News-ID: 3993469 • Views: …
More Releases from ABNewswire
Author's Tranquility Press Releases: "The Long Goodbye: Loving Her Until the End …
A Husband's Unshakable Love Through the Silent Storm of Alzheimer's
There is a grief that begins before the final breath.
It creeps in quietly when the person you love forgets your name.
When their smile no longer meets recognition.
When you're still holding their hand, but they're slipping further away.
In A Caregiver's Tips: My Wife Had Alzheimer's Disease [https://www.amazon.com/Caregivers-Tips-Frederic-Buse/dp/1966088353/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.UA1r0fAoj8ZKU782MKluzgCzoWDCeUIPwYBv_nrgSB-WU0PXLZ_My8_ansmgGV2OzG-qa9na8TPe__njO-fPGZxphzfEy9kb5Xs3WHc0SohWXVwnH0nYktt0pWTPTSG2klRUw1x-ykYDxL9CRt9rkMegygfu1J3FMqL05sG6W1uhRRbT2jBkf8MGZoGNqFhGznWQg28fn5UK-vR0Im-RYsV7qo53_eTOzjcRC5meFfY.aXtm73DERBs1Lo-OxjLdNVwCE42Zk-Hj8bIdlPajzTE&qid=1753450694&sr=1-1], Fred Buse does not just recount this journey-he invites you inside it. This tender, heart-rending…
Uber Realty Reaffirms Independence and Unveils Bold 1% Listing Fee Model in Flor …
Niceville, FL - As Compass finalizes its acquisition of Anywhere Real Estate, Uber Realty LLC today publicly affirms its full independence and doubles down on its mission: local homeowners should not be forced to pay 5-6% commissions just because the industry hasn't caught up. Uber Realty remains a locally rooted firm, committed to offering true transparency and fair pricing to sellers in Niceville, Shalimar, Fort Walton Beach, and across Okaloosa…
Cigo Tracker Unveils Real-Time Heavy Equipment Tracking Solution for Constructio …
Image: https://www.abnewswire.com/upload/2025/09/bc595833ad3f1128b5d51459d6675e20.jpg
In industries such as construction, mining, oil and gas, and logistics, heavy equipment forms the backbone of operations. These assets, ranging from excavators and bulldozers to cranes and trucks, are not only expensive but also critical to project success. Yet, without proper monitoring, businesses face challenges such as asset theft, inefficient usage, high maintenance costs, and project delays. This is where heavy equipment tracking steps in as a game-changer.…
Borrow Smarter: Radcred Highlights Lower Personal Loan Costs After Fed Rate Redu …
News broke in September 2025 that the Federal Reserve trimmed its benchmark rate by 25 basis points to 4.00-4.25 percent. This move ripples through credit card APRs, auto loans, and, most importantly, personal loan interest rates. Lower benchmark rates generally encourage lenders to reduce their APRs, creating a window of opportunity for borrowers to lock in affordable personal loans.
RadCred's AI-powered loan matching platform helps you act quickly, comparing hundreds of…
More Releases for Rheumatoid
Rheumatoid Arthritis Pipeline Outlook Report 2024
DelveInsight's, "Rheumatoid Arthritis Pipeline Insight 2024" report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Rheumatoid Arthritis Therapeutics Market - Relieving Pain, Restoring Mobility: R …
Newark, New Castle, USA: The "Rheumatoid Arthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Rheumatoid Arthritis Therapeutics Market: https://www.growthplusreports.com/report/rheumatoid-arthritis-therapeutics-market/7891
This latest report researches the industry structure,…
How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis
- New findings support research-based kit for management of Rheumatoid Arthritis
Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively.
Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data…
Major Advancements| Competitor Landscape: Rheumatoid Arthritis
Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports.
Competitor Landscape: Rheumatoid Arthritis
Summary
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during…
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers
Classification of Rheumatoid Arthritis Drugs
3.1…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
